Literature DB >> 10357919

Lower limb ischemia: phase 1 results of salvage perfusion.

P M Walker1, A D Romaschin, S Davis, J Piovesan.   

Abstract

Revascularization of an ischemic lower extremity is associated with high morbidity (20-30%) and perioperative mortality (10-20%) regardless of the mode of intervention, surgical or thrombolytic, considered to be due to polymorphonuclear (PMN) activation and mediator release. In this study, the safety and feasibility of cell-free extracorporeal perfusion of the limb with a solution designed to minimize both local and systemic injury was tested. Methods. Patients with severe limb ischemia (sensory/motor loss, rest pain/gangrene) were studied prospectively by random assignment into the treatment arm (n = 14) or control arm (n = 21). Surgical management consisted of restorative procedure, thrombectomy or embolectomy (n = 21), or reconstruction (n = 14). Reperfusion of the ischemic limb was achieved with hypertonic, hyperoncotic perfusate containing anti-oxidants delivered via the arterial tree (mean volume 1835 +/- 824 ml) with initial venous drainage (mean volume 775 +/- 263 ml) in the restorative group. Means were compared by paired t test. Results. No adverse systemic effects were detected after limb perfusion (electrolytes, coagulation, platelet function, CBC). Rapid lactate wash-out was observed within 30 min of perfusion (preperfusion 3.2 +/- 4.1 mM, 30 min postperfusion 0.7 +/- 0.71 mM, P < 0.01). Blunting of PMN activation was shown by chemiluminescence (CL) analysis (preischemic CL: 0.68 +/- 0.2; 30 min CL: 0.47 +/- 0. 2; P < 0.013). F2-isoprostanes, a marker of free radical-mediated systemic lipid peroxidation, were significantly reduced in patients treated with study perfusion method (70.55 +/- 39.54 versus control 194.38 +/- 25.24, P < 0.005). Mortality with treatment was 0/14 versus 5/21 in the control. Complication frequency: MI 0/14 vs 3/21; renal 0/14 vs 1/21; leg edema 1/14 vs 5/21; amputations 2/14 vs 1/21. Conclusion. Modification of limb perfusion in patients with severe limb ischemia, using our simple and rapid (15-20 min) method provides beneficial systemic effects. Copyright 1999 Academic Press.

Entities:  

Mesh:

Year:  1999        PMID: 10357919     DOI: 10.1006/jsre.1999.5641

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  3 in total

1.  Assessment of biochemical markers in patients with pain of vascular origin.

Authors:  Richard Rokyta; Anna Yamamotová; Richard Sulc; Ladislav Trefil; Jaroslav Racek; Vladislav Treska
Journal:  Clin Exp Med       Date:  2008-09-19       Impact factor: 3.984

2.  Postischemic treatment with ethyl pyruvate prevents adenosine triphosphate depletion, ameliorates inflammation, and decreases thrombosis in a murine model of hind-limb ischemia and reperfusion.

Authors:  Robert S Crawford; Hassan Albadawi; Marvin D Atkins; John J Jones; Mark F Conrad; William G Austen; Mitchell P Fink; Michael T Watkins
Journal:  J Trauma       Date:  2011-01

3.  The Toronto prehospital hypertonic resuscitation-head injury and multi organ dysfunction trial (TOPHR HIT)--methods and data collection tools.

Authors:  Laurie J Morrison; Sandro B Rizoli; Brian Schwartz; Shawn G Rhind; Merita Simitciu; Tyrone Perreira; Russell Macdonald; Anna Trompeo; Donald T Stuss; Sandra E Black; Alex Kiss; Andrew J Baker
Journal:  Trials       Date:  2009-11-20       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.